Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $218 | 35 days | |
5 mg | $978 | 35 days | |
10 mg | $1,840 | 35 days |
Description | ERX-41 is an orally active, stereospecific small molecule that targets lysosomal acid lipase A (LIPA). It induces endoplasmic reticulum (ER) stress, leading to cell death independently of its LIPA activity yet reliant on its ER localization, suggesting a role in targeted solid tumor therapies [1]. |
In vitro | ERX-41 (1 μM; 0-30 h) induces cell death in MDA-MB-231 cells without significantly affecting normal human mammary epithelial cells (HMECs) [1]. Additionally, ERX-41 (1 μM; 2 h, 4 h) causes rapid endoplasmic reticulum expansion and peripheral endoplasmic reticulum disarray within 4 hours and 2 hours, respectively [1]. Moreover, ERX-41 (1 μM; 0.5-4 h) activates the unfolded protein response (UPR) pathway by promoting p-PERK and p-eIF2-α [1]. |
In vivo | ERX-41 (10 mg/kg; oral or intraperitoneal injection; single dose) is detectable within the tumor 1.5 hours post-administration, regardless of the administration route [1]. A single oral dose of ERX-41 at 10 mg/kg significantly inhibits tumor progression in both the MDA-MB-231 and D2A1 xenograft mouse models without affecting mouse body weight [1]. |
Molecular Weight | 704.81 |
Formula | C38H48N4O9 |
Cas No. | 2440087-54-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.